How does Nuvaxovid (NVX‑CoV2373) compare to the mRNA COVID‑19 vaccines (Pfizer‑BioNTech, Moderna) regarding efficacy, safety, storage requirements, and approved age groups?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Nuvaxovid vs mRNA COVID-19 Vaccines: Key Differences

Both Nuvaxovid (NVX-CoV2373) and mRNA vaccines (Pfizer-BioNTech, Moderna) are recommended by ACIP for COVID-19 vaccination in persons aged ≥6 months, with the choice between them being acceptable for most individuals aged ≥12 years 1.

Age Group Approvals

The approved age ranges differ significantly between vaccine types:

  • mRNA vaccines (Moderna, Pfizer-BioNTech): Authorized for ages ≥6 months 1
  • Nuvaxovid: Only authorized for ages ≥12 years 1, 2

For children aged 6 months to 11 years, mRNA vaccines are the only option available. Nuvaxovid is specifically limited to adolescents 12-17 years with at least one high-risk underlying condition 2.

Efficacy Against COVID-19

Symptomatic Disease Prevention

High-certainty evidence demonstrates that both vaccine types substantially reduce symptomatic COVID-19:

  • mRNA vaccines: 93-98% efficacy (Moderna: 93.20%, Pfizer: 97.84%) 3
  • Nuvaxovid: 83% efficacy (moderate-certainty evidence) 3

Severe Disease Prevention

Both platforms provide robust protection against severe/critical COVID-19:

  • mRNA vaccines: 95-98% efficacy 3
  • Nuvaxovid: 100% efficacy (95% CI: 87-100%), though based on moderate-certainty evidence 3

Real-World Comparative Effectiveness

Recent South Korean data suggests Nuvaxovid may provide superior protection as a booster dose. In adolescents receiving a third dose, the adjusted hazard ratio for medically attended COVID-19 was 0.68 (95% CI: 0.54-0.84), indicating 32% lower risk with Nuvaxovid compared to Pfizer 4. Among adults, Nuvaxovid showed comparable protection against infection but significantly better protection against severe disease (aHR 0.39,95% CI: 0.20-0.75) 5.

Safety and Reactogenicity Profile

Serious Adverse Events

Both vaccine types demonstrate acceptable safety profiles with no significant differences in serious adverse events compared to placebo 3. However, Nuvaxovid demonstrates substantially lower reactogenicity (local and systemic side effects) compared to mRNA vaccines 6.

Specific Adverse Reactions

Myocarditis/pericarditis risk differs markedly:

  • mRNA vaccines: Well-established increased risk, particularly in males aged 12-17 years after second dose 7
  • Nuvaxovid: Myocarditis/pericarditis reported in post-marketing surveillance but appears less frequent 2

Reactogenicity Comparison

A targeted review found that mRNA boosters cause significantly more side effects than Nuvaxovid. Compared to Nuvaxovid, individuals receiving mRNA boosters experienced higher rates of:

  • Pain/tenderness, swelling, erythema: 0.4-41.6% absolute increase (Pfizer) and 5.5-55% absolute increase (Moderna)
  • Systemic symptoms (fatigue, headache, muscle pain, fever): Similar magnitude of increases 6

This lower reactogenicity profile may be particularly relevant for vaccine-hesitant individuals or those who experienced significant side effects with prior mRNA doses.

Storage Requirements

Nuvaxovid offers significant logistical advantages:

  • Standard refrigeration (2-8°C) for up to 6 months 2
  • Does not require ultra-cold storage like mRNA vaccines
  • More practical for resource-limited settings and smaller healthcare facilities

Dosing Schedules

Primary Series (Unvaccinated Individuals)

  • mRNA vaccines: Single dose for ages ≥5 years 1
  • Nuvaxovid: Two doses required, 3-8 weeks apart for unvaccinated individuals aged ≥12 years 1

This represents a practical disadvantage for Nuvaxovid in primary vaccination.

Booster Doses

For previously vaccinated individuals, all three vaccines require only a single booster dose with ≥8 weeks interval from the last dose 1.

Immunocompromised Patients

Both vaccine types are acceptable for immunocompromised individuals:

  • mRNA vaccines: 3-dose primary series recommended 1
  • Nuvaxovid: 2-dose primary series acceptable 1

The CDC provides specific guidance for this population regardless of vaccine choice 2.

Antibody Response Characteristics

Nuvaxovid demonstrates slower antibody decay compared to mRNA vaccines. While bivalent mRNA vaccines elicit higher peak antibody responses, neutralization levels converge by 12 months post-vaccination. The geometric mean antibody fold-change (day 360/day 28) was significantly higher for Nuvaxovid (0.51) compared to monovalent mRNA (0.31, p=0.010) and bivalent mRNA (0.35, p=0.017) 8.

Clinical Decision-Making Algorithm

For most individuals aged ≥12 years, either vaccine type is acceptable 1. Consider Nuvaxovid specifically when:

  1. History of significant reactogenicity with prior mRNA doses (severe local/systemic reactions)
  2. Concern about myocarditis risk in adolescent males
  3. Vaccine hesitancy related to mRNA technology
  4. Storage/logistics favor standard refrigeration

Choose mRNA vaccines when:

  1. Patient is aged <12 years (only option available)
  2. Single-dose primary series is preferred for compliance
  3. Immediate availability is prioritized

Important Caveats

  • Pregnant women were excluded from trials; insufficient data exists for vaccine-associated risks in pregnancy for both platforms 2
  • Most trial data predates current circulating variants, though both 2024-2025 formulations target Omicron JN.1 lineage 1
  • Long-term comparative effectiveness data beyond 12 months remains limited

References

3
Research

Efficacy and safety of COVID-19 vaccines.

The Cochrane database of systematic reviews, 2022

Related Questions

What are the differences between available Covid-19 vaccines, such as Pfizer (mRNA vaccine) and AstraZeneca (viral vector vaccine)?
What is the difference between Spikevax (Moderna COVID-19 vaccine) and mNexspike?
What is the difference in cost and availability between Mspikevax (Moderna COVID-19 vaccine) and Spikevax (Moderna COVID-19 vaccine) in terms of production volume?
What Covid-19 vaccine recommendations are suitable for a 57-year-old male with no recent vaccine history?
In a hospitalized patient with kidney, liver, and lung infections and a white blood cell count of 334 × 10⁹/L, what is the likely significance and recommended management?
What is the appropriate hydroxyurea dosing regimen for essential thrombocythemia?
What is the appropriate management for nausea and dry mouth in a hospice patient with interstitial lung disease?
How should a 4½‑year‑old child with a six‑day history of fever and dry cough, now afebrile and asymptomatic, be evaluated and managed?
Between radioactive iodine (RAI) therapy for Graves disease and radioactive iodine (RAI) therapy for toxic multinodular goiter, which condition has a higher risk of permanent hypothyroidism?
What is the typical natural course and expected duration of fever and dry cough in a previously healthy 4½‑year‑old child?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.